Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines

William H. Chappell; Saverio Candido; Stephen L. Abrams; Shaw M. Akula; Linda S. Steelman; Alberto M. Martelli; Stefano Ratti; Lucio Cocco; Melchiorre Cervello; Giuseppe Montalto; Ferdinando Nicoletti; Massimo Libra; James A. McCubrey

doi:doi:10.18632/aging.103377

← Back

Research Paper Volume 12, Issue 11 pp 10194—10210

Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines

Figure 6. Effects of introduction of WT-TP53 on the chemosensitivity of doxorubicin-sensitive and doxorubicin-resistant DU145 cells. The IC₅₀s of doxorubicin-sensitive and doxorubicin-resistant DU145 and DU145 + WT-TP53 cells to: Panel (A) Doxorubicin, Panel (B) Cisplatin, (C) Paclitaxel and (D) 5-Fluorouracil were determined by MTT analysis as described in Figure 4. These experiments were repeated three times and similar results were obtained. Statistical analysis is presented on the panels. *** = P < 0.0001.